The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model

被引：43
作者：
Pinto, Laine Celestino [1 ]
Soares, Bruno Moreira [1 ]
Viana Pinheiro, Joao de Jesus [2 ]
Riggins, Gregory J. [3 ]
Assumpcao, Paulo Pimentel [1 ]
Rodriguez Burbano, Rommel Mario [1 ]
Montenegro, Raquel Carvalho [1 ]
机构：
[1] Fed Univ Para, Inst Biol Sci, BR-66059 Belem, Para, Brazil
[2] Fed Univ Para, Hlth Sci Inst, BR-66059 Belem, Para, Brazil
[3] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21231 USA
来源：
TOXICOLOGY IN VITRO | 2015年 / 29卷 / 08期
关键词：
Mebendazole; Migration; Invasion; Metalloproteinase; PHASE-II TRIAL; FOLINIC ACID; IN-VITRO; COLON-CANCER; 5-FLUOROURACIL; EXPRESSION; PACLITAXEL; CISPLATIN; FLUOROURACIL; COMBINATION;
D O I：
10.1016/j.tiv.2015.08.007
中图分类号：
R99 [毒物学（毒理学）];
学科分类号：
100405 ;
摘要：
The present study aimed to investigate the effects of MBZ on a human malignant ascites cell line derived from a primary gastric cancer tumor. Our data reveal that MBZ showed high cytotoxicity in vitro, displaying an IC50 of 0.39 mu M and 1.25 mu M in ACP-02 and ACP-03, respectively. The association between MBZ and 5-FU increased slightly the cytotmdcity when compared to MBZ and 5-FU alone. Furthermore, MBZ disrupted the microtubule structure of AGP-01 cells and inhibited significantly the invasion and migration of these cells. Activity of active MMP-2 significantly decreased at all tested concentration of MBZ compared to negative control. These results support the indication of MBZ in combination with chemotherapeutic agents as a possible adjuvant therapy for the management/treatment of patients with advanced gastric cancer since MBZ is a drug of low cost with acceptable safety profile and reduced toxicity to normal cells. However, clinical trials must be performed in o to evaluate its efficacy in gastric cancer patients. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2038 / 2044
页数：7
相关论文
共 59 条
[1]   FUNCTION AND RECEPTOR SPECIFICITY OF A MINIMAL 20-KILODALTON CELL ADHESIVE FRAGMENT OF FIBRONECTIN [J].
AKIYAMA, SK ;
AOTA, S ;
YAMADA, KM .
CELL ADHESION AND COMMUNICATION, 1995, 3 (01) :13-25
[2]   Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer [J].
Al-Batran, SE ;
Atmaca, A ;
Hegewisch-Becker, S ;
Jaeger, D ;
Hahnfeld, S ;
Rummel, MJ ;
Seipelt, G ;
Rost, A ;
Knuth, JOA ;
Jaeger, E .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (04) :658-663
[3]  
ALBINI A, 1987, CANCER RES, V47, P3239
[4]  
Aquino A, 1998, CLIN CANCER RES, V4, P2473
[5]   Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme [J].
Bai, Ren-Yuan ;
Staedtke, Verena ;
Aprhys, Colette M. ;
Gallia, Gary L. ;
Riggins, Gregory J. .
NEURO-ONCOLOGY, 2011, 13 (09) :974-982
[6]  
BHALLA K, 1993, LEUKEMIA, V7, P563
[7]   Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic,gastric cancer:: A Federation Francophone de Cancerologie Digestive Group Study -: FFCD 9803 [J].
Bouche, O ;
Raoul, JL ;
Bonnetain, F ;
Giovannini, M ;
Etienne, PL ;
Lledo, G ;
Arsène, D ;
Paitel, JF ;
Guérin-Meyer, V ;
Mitry, E ;
Buecher, B ;
Kaminsky, MC ;
Seitz, JF ;
Rougier, P ;
Bedenne, L ;
Milan, C .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) :4319-4328
[8]   Gastric cancer [J].
Catalano, V ;
Labianca, R ;
Beretta, GD ;
Gatta, G ;
de Braud, F ;
Van Cutsem, E .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 54 (03) :209-241
[9]   Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer [J].
Chao, Y ;
Yeh, KH ;
Chang, CJ ;
Chen, LT ;
Chao, TY ;
Wu, MF ;
Chang, CS ;
Chang, JY ;
Chung, CY ;
Kao, WY ;
Hsieh, RK ;
Cheng, AL .
BRITISH JOURNAL OF CANCER, 2004, 91 (03) :453-458
[10]   Treatment of Malignant Ascites [J].
Chung, Michael ;
Kozuch, Peter .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2008, 9 (2-3) :215-233
123456